“Cheapest GLP-1” has a different answer depending on one question you can settle in ten minutes: what kind of coverage, if any, do you have. The spread between the best and worst answer is roughly $6,000 a year for the same class of drug, and most of that gap is decided by paperwork rather than by shopping.
This guide walks every route a person in the United States could actually use in September 2026, in the order you should check them, with what each one costs. Every price was pulled on September 4, 2026 from the manufacturers’ own self-pay pages and the federal program pages, and cross-checked the same day against the federal TrumpRx.gov listings, which matched dose for dose. Prices here change several times a year. This is cost and navigation only, and which drug is appropriate for you is a question for a prescriber.
Step 1: Find Out Whether an Approved Indication Makes It Covered
Do this before you price anything, because coverage beats every cash route by a wide margin, and it often hinges on why the drug is being prescribed rather than on the drug itself. Plans that exclude “weight loss drugs” as a category frequently still cover the same molecules for a different approved use. Medicare’s own rules acknowledge the asymmetry: Medicare.gov states you are not eligible for the GLP-1 Bridge if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, precisely because your Part D plan may already cover the drug for those conditions.
Ask your plan two questions in writing: is this molecule on the formulary for any indication at all, and is it excluded as a weight-loss drug specifically or excluded entirely.
Step 2: If You Have Medicare Part D, Check the GLP-1 Bridge First
This is the cheapest route in the country and it is easy to miss. CMS launched the Medicare GLP-1 Bridge on July 1, 2026 as a short-term demonstration running through December 31, 2027, and eligible Part D beneficiaries pay a flat $50 copay per month.
Medicare.gov lists the covered drugs narrowly: Foundayo tablets, Wegovy (injection or tablet), and the Zepbound KwikPen only. Single-dose Zepbound vials and pens are not covered, so the device on the prescription decides whether you qualify.
Eligibility, per Medicare.gov, is age 18 or older plus one of: a BMI of 35 or higher; a BMI of 30 or higher with diastolic heart failure, uncontrolled high blood pressure, or stage 3a or higher chronic kidney disease; or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
One cost detail before you count on it: CMS states the Bridge operates outside the Part D benefit’s payment flow, so the deductible does not apply, none of the $50 counts toward your true out-of-pocket costs, and there is no low-income subsidy on it. Your prior authorization runs through December 31, 2027 including refills and dose changes, unless you switch GLP-1s. Our Medicare GLP-1 coverage guide covers the program in full.
Step 3: If You Have Commercial Coverage, Use the Manufacturer Savings Card
Every major GLP-1 has a card, and every card requires commercial insurance. On September 4, 2026, NovoCare listed Wegovy at as little as $25 a month subject to a maximum saving of $100 a month, and Ozempic at as little as $25 a month for up to three months with the same $100 cap and government beneficiaries excluded. LillyDirect listed Foundayo at as low as $25 a month for the commercially insured with coverage, and the Zepbound single-dose pen at as low as $25 a month for up to a three-month prescription.
Read the cap, not the headline. A $100 monthly savings maximum means a $400 copay becomes $300, not $25. The card only reaches $25 when your plan has already done most of the work. Our Zepbound savings card guide walks one of these terms line by line.
If you have no insurance at all, skip this step. These cards exclude you by design.
Step 4: Paying Cash? Buy Direct, and Buy the Tablet
For a true cash payer the manufacturers’ own self-pay channels are the whole game, and as of September 2026 the oral GLP-1s are the cheapest entry point in the class.
| Route | Who it is for | Cash cost per month |
|---|---|---|
| Medicare GLP-1 Bridge | Part D beneficiaries meeting the criteria | $50 |
| Manufacturer savings card | Commercial plan that covers the drug | $25, capped at $100 saved |
| Foundayo (orforglipron) tablets | Anyone paying cash | $149 start, $199 mid, $299 maintenance |
| Wegovy tablets | Anyone paying cash | $149 start, $199 mid, $299 maintenance |
| Wegovy pen | New self-pay patients | $199 for two fills, then $349; $399 for the 7.2 mg HD pen |
| Zepbound KwikPen or vials | Cash payers without government insurance | $299, $399, then $449 at 7.5 mg and above |
| Ozempic pen | New self-pay patients | $199 for two fills, then $349; $499 at 2 mg |
| Generic liraglutide | See Step 6 | Roughly $715 in acquisition cost at the weight-loss dose |
| Phentermine 37.5 mg (not a GLP-1) | Anyone | About $2.13 for 30 tablets in acquisition cost |
Lilly’s Foundayo page prices the tablets at $149 for the 0.8 mg and 2.5 mg doses, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg and 17.2 mg, defining a month as 30 days. Novo Nordisk’s Wegovy page prices its tablets at $149 for 1.5 mg, $199 for 4 mg and $299 for both 9 mg and 25 mg, a month being one bottle of 30 tablets. LillyDirect prices the Zepbound KwikPen and the four-vial pack identically at $299, $399 and $449 by dose.
Some of that is temporary. Lilly’s footnote states the 2.5 mg and 5.5 mg Foundayo prices are “temporarily reduced through December 31, 2026.” Novo’s Wegovy page carries a parallel warning, “Pricing to be updated after December 31, 2026,” and the $199 pen rate is scoped to new patients, two monthly fills, and the 0.25 mg and 0.5 mg doses only.
See Foundayo cost, orforglipron cost, GLP-1 pills cost and oral Wegovy cost for the tablet detail, and the cheapest way to get Zepbound for that drug specifically.
Step 5: Protect the Refill Window, Because It Is Priced
The $449 Zepbound price on the four highest doses is conditional. LillyDirect’s footnote states that regular prices apply if the prescription is not refilled within 45 days: $499 at 7.5 mg and $699 at 10 mg, 12.5 mg and 15 mg. Lilly’s Foundayo page applies the same 45-day condition to its two highest doses.
On a Zepbound maintenance dose that is $250 for one late fill. Start the clock on the delivery date, not the order date, set the reminder for day 30, and order the refill before the current supply runs out, because the window is measured on the purchase.
Step 6: Know Why the Only Generic GLP-1 Is Not the Cheap One
Liraglutide is the only GLP-1 with generic competition, and people reasonably assume that makes it the budget option. The numbers say otherwise.
CMS National Average Drug Acquisition Cost data effective August 19, 2026 prices generic liraglutide 18 mg per 3 mL at $33.82 per milliliter in a two-pen pack, $32.00 in a three-pen pack, and $47.69 in a five-pen pack. Those pens run 6 mg per milliliter, so at the 3 mg daily dose used for weight management you go through about 15 mL in 30 days: roughly $480 to $715 a month in what the pharmacy pays before any markup or dispensing fee.
That is more than branded Zepbound or Wegovy cost through the manufacturers’ own channels, for an older drug that requires a daily injection instead of a weekly one. At the lower diabetes dose the arithmetic improves, roughly $288 a month in acquisition cost at 1.8 mg daily, but that is not the weight-management dose. Our Saxenda cost guide covers the branded version.
Step 7: The Honest Floor Is an Older, Cheaper, Non-GLP-1 Drug
If the question is genuinely “what is the least I can spend on a prescription weight-loss medication,” the answer is not a GLP-1 at all. CMS acquisition-cost data effective August 19, 2026 puts phentermine 37.5 mg at $0.07085 per tablet, which is about $2.13 for a 30-day supply, and generic phentermine-topiramate ER at $3.14 to $3.29 per capsule, or roughly $94 to $99 for 30. Those are pharmacy acquisition costs rather than what you will be quoted, but the order of magnitude is real.
These are different drugs with different effect sizes and different suitability, all of which is a conversation for a prescriber rather than a cost guide. But nobody should spend $299 a month without knowing that a $10 prescription exists. See our guides to phentermine, Qsymia and Contrave.
Step 8: Do Not Treat Compounded GLP-1s as a Discount
Compounded semaglutide and tirzepatide were the cheap route in 2023 and 2024, and the legal picture has changed repeatedly since. Here is where it stands on FDA’s compounder policy page, last updated April 1, 2026.
Neither tirzepatide nor semaglutide currently appears on the 503B bulks list or on FDA’s drug shortage list, and outsourcing facilities generally cannot compound from a bulk substance unless one of those conditions is met. For state-licensed pharmacies and physicians compounding under section 503A, the enforcement-discretion periods tied to the shortage ended in 2025 for both molecules.
FDA also states it treats a compounded product as “essentially a copy” of a commercially available drug when it has the same active ingredient at the same, similar or easily substitutable strength by the same route, and it applies that test to combinations too, naming semaglutide plus vitamin B12 as an example. The one live exception is narrow: FDA says it does not currently intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.
The translation for a buyer is not that compounding is banned. It is that a seller offering compounded GLP-1s at volume is operating against the grain of the policy FDA has published, and a price advantage there is not the same thing as a savings tactic.
Step 9: Price the Telehealth Middleman Separately
Telehealth weight-loss sellers do not get better drug prices. They resell the manufacturer self-pay prices and charge a membership on top, generally $74 to $149 a month, which is $888 to $1,788 a year for the same medicine. Our Ro cost guide and Hims cost guide price both.
That fee is not automatically waste. It buys a prescriber you can reach and, usually, somebody to file your prior authorization and appeal a denial. With commercial coverage worth fighting for, it can pay for itself in a month. With no coverage at all, you are paying a concierge to place an order you could place yourself.
One caution on discount cards: Medicare.gov warns that TrumpRx and other discount cards are not creditable coverage, so anything you buy with one does not count toward your deductible or out-of-pocket maximum. Our GoodRx vs. SingleCare comparison covers where those cards do help.
The Bottom Line
Check coverage first, because it is worth more than anything you can negotiate. On Medicare Part D and meeting the criteria, $50 a month through the GLP-1 Bridge beats everything, at least until it expires on December 31, 2027. With a commercial plan that covers the drug, a savings card gets you toward $25 under a $100 monthly cap.
Paying cash, the cheapest FDA-approved GLP-1 in September 2026 is a tablet at $149 a month to start and $299 at maintenance, bought straight from Lilly or Novo Nordisk with no middleman. The cheapest prescription weight-loss drug of any kind is phentermine, at roughly two dollars a month in acquisition cost. And the cheapest thing on this page is the ten minutes you spend on Step 1. For the whole class priced side by side, see GLP-1 costs without insurance.